Consider the CV Benefits of Different SGLT2 Inhibitors

January 2019

You'll hear more about the CV benefits of SGLT2 inhibitors (canagliflozin, etc).

Reps will say canagliflozin (Invokana) is now approved to reduce CV events in adults with type 2 diabetes and CV disease...while empagliflozin (Jardiance) is only approved to reduce CV death.

But canagliflozin's approval is based on nonsignificant reductions in CV death, MI, or stroke...lumped into a significant composite outcome.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote